Post-Recovery Combination Program: Topical + Breath + Oral on One COA Chain

Recovery buyers piece their kits together from three brands with three documentation standards. This playbook shows how to ship the coordinated answer — topical, breath, oral — on one COA chain.s — no brand offers a coordinated multi-format recovery program on one documentation chain.

01 · The problem

The recovery buyer (post-procedure, post-illness, post-fatigue) needs three things at once: topical comfort, breathing-easy rituals, and daily oral support. The shelf answers in three aisles from three brands with three documentation standards — no coordination, no combined story, no volume economics. That coordinated program is the open shelf position — and nobody claims it yet.

02 · Scientific rationale

Multi-route support works when every component shares a characterization baseline: topical barrier formats for the comfort phase, a breathing-reset mist ritual for the low-activity weeks, and oral liquid support for the routine continuum. One platform, one QC panel, one COA chain — the combination reads as one system, not three SKUs in a box.

03 · Program documentation

Protocol documentation for this program family is maintained in TONGNIAN's internal files — network-clinic protocol series and anonymized case records where applicable [5]. Partner access under NDA; the evidence hierarchy stays explicit — published reviews first, internal observational programs second, case documentation third. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line — closed-tubing culture, scheduled harvest, tangential-flow separation and concentration, sterile filtration — with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [3].

Fig. 1 — The combination map: three routes, one baseline.

06 · Regulatory pathway: EU & US first

Per-component routes: topical cosmetic track, wellness-routine mist positioning, oral supplement framework (US DSHEA / EU novel food) — each documented, none overlapping into therapeutic territory. The combination is merchandised as a program, not a kit of claims.

07 · Expected outcomes

• Basket economics: a three-SKU program built on one story lifts average order value compared with selling recovery items as standalone SKUs.
• Channel fit: pharmacy-adjacent and recovery-retail shelves get a coordinated set.
• One documentation chain simplifies channel onboarding.

No claims are made beyond the cosmetic, supplement, or professional-use framing of the destination market — authority comes from documentation and batch measurement.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label and program naming run through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Systematic review of 19 human studies of topical exosome skin applications, 2026 — summary via DermatologyNews.net.
3. Ávila-Gálvez MÁ, et al. Oral delivery of ellagic acid encapsulated in milk exosomes. Mol Nutr Food Res. 2026.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17), national standard — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).